Company news

Tempus AI, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Tempus Announces Study Highlighting the Role of Advanced Genomic Profiling Features in Identifying Clinically Actionable Findings

March 10, 2026

Tempus Announces Strategic Collaboration Agreement with Merck to Accelerate AI-Driven Precision Medicine

March 3, 2026

Tempus to Participate in the Morgan Stanley Technology, Media & Telecom Conference

February 26, 2026

Tempus Reports Fourth Quarter and Full Year 2025 Results

February 23, 2026

Tempus Announces Novel Pan-Cancer HRD-RNA Algorithm

February 18, 2026

Tempus Announces Collaboration with Median Technologies to Integrate AI-Powered Lung Cancer Screening into the Pixel Platform

February 11, 2026

Tempus to Report Fourth Quarter and Full Year 2025 Financial Results on February 24

February 10, 2026

Ambry’s Contributions to MAVEs Support Thousands of Patient Reclassifications and Expand to New Genes

February 3, 2026

Ambry Genetics Announces One Millionth Test Leveraging RNA to Improve Diagnostic Accuracy and Yield

February 1, 2026

Tempus Reveals Its AI-Driven IPS Test More Accurately Predicts Immunotherapy Benefit Compared to Conventional Biomarkers

January 27, 2026

Tempus Announces the Launch of Paige Predict

January 21, 2026

Tempus and NYU Langone Health Announce Strategic Collaboration to Advance Precision Oncology

January 12, 2026

Northwestern Medicine Selects Tempus to Expand Genomic Testing

January 11, 2026

Tempus Achieves Record Total Contract Value Exceeding $1.1 Billion

January 11, 2026

Tempus Announces Preliminary Fourth Quarter and Full Year 2025 Results

January 10, 2026

Tempus Announces Eight Abstracts Accepted for Presentation at the 2026 ASCO® Gastrointestinal Cancers Symposium

January 8, 2026

Tempus to Present at 44th Annual J.P. Morgan Healthcare Conference

January 5, 2026

Tempus Announces Ten Abstracts Accepted for Presentation at the 2025 San Antonio Breast Cancer Symposium

December 8, 2025

Tempus to Participate in the Piper Sandler 37th Annual Healthcare Conference

November 17, 2025

Tempus and IFLI Announce Study to Advance Follicular Lymphoma Research

November 13, 2025

Tempus Announces Six Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer Annual Meeting 2025

November 4, 2025

Tempus Reports Third Quarter 2025 Results

November 3, 2025

Tempus to Participate in the Stifel 2025 Healthcare Conference

October 27, 2025

Tempus to Report Third Quarter 2025 Financial Results on November 4

October 20, 2025

Ambry Genetics Announces 10-Year Study in Genetics in Medicine Highlighting the Impact of Proactive Exome Reanalysis for Healthcare Equity

October 19, 2025

Tempus Announces Collaboration with Whitehawk Therapeutics to Advance Biomarker-Driven Oncology Research

October 15, 2025

Tempus Announces Six Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025

October 14, 2025

Tempus Selected by ARPA-H to Provide CRO and Testing Services for the ADAPT Program, Advancing Precision Cancer Therapy

October 8, 2025

Ambry Genetics Announces Improved EHR-Integrated Breast Cancer Risk Assessment Solution with Upgraded Tyrer-Cuzick Scoring Approach Incorporating Breast Density

September 30, 2025

Tempus Receives U.S. FDA 510(k) Clearance for Tempus xR IVD, its RNA NGS In Vitro Diagnostic Device

September 21, 2025

Renalytix Announces Collaboration with Tempus to Advance Intelligent Risk Assessment in Diabetic Kidney Disease

September 14, 2025

Tempus Receives U.S. FDA Special 510(k) Clearance for Updated Tempus Pixel Device

September 10, 2025

Tempus Announces New Study in JCO Precision Oncology Validating PurIST® Algorithm for Enhanced Therapy Selection in Pancreatic Cancer

September 8, 2025

Northwestern Medicine Becomes First Health System to Integrate Tempus’ Generative AI Co-Pilot, David, Into Its EHR Platform

September 3, 2025

Tempus to Participate in Morgan Stanley’s 23rd Annual Global Healthcare Conference

September 2, 2025

Tempus Announces the Acquisition of Paige

August 21, 2025

Tempus Reports Second Quarter 2025 Results

August 7, 2025

Tempus to Report Second Quarter 2025 Financial Results on August 8

July 21, 2025

Tempus Receives U.S. FDA 510(k) Clearance for Tempus ECG-Low EF Software

July 15, 2025

Tempus Expands AI-Enabled Care Pathway Intelligence Platform into Breast Cancer

July 7, 2025

Tempus Announces Pricing of Upsized Offering of $650 Million of Convertible Senior Notes

June 29, 2025

Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense

June 29, 2025

Ambry Genetics’ CARE Program Validated for Accuracy in Identifying High-Risk Patients for Hereditary Cancer Testing

June 24, 2025

Tempus to Participate in TD Cowen’s 4th Annual Tools/Dx Revolution Conference

June 16, 2025

Tempus Announces Collaboration with Northwestern University’s Abrams Research Center on Neurogenomics to Leverage AI for Alzheimer’s Disease Research

June 11, 2025

Tempus Introduces xM, An Assay to Monitor Immunotherapy Response for Patients with Advanced Cancers

June 1, 2025

Introducing Tempus One in the EHR with Integrated Guidelines

May 31, 2025

Tempus Introduces Fuses, A Program Designed to Transform Therapeutic Research and Build the Largest Diagnostic Platform Using its Novel Foundation Model

May 30, 2025

Tempus Announces 10 Abstracts Accepted for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting

May 29, 2025

A Decade of Discovery: Tempus Supported Almost 1,500 Research Projects in 10 Years

May 27, 2025

← Newer news releases · Older news releases →

Calls

The 5 newest of 10 calls. Every call is listed under its year.

Decks

The 5 newest of 16 decks. Every deck is listed under its year.